Liu Tianying, Ma Mintao
Department of Ultrasonography, Xidian Group Hospital, Xi'An, 710077, China.
Department of Ultrasound, The Affiliated Hospital of Northwest University/Xi'An No.3 Hospital, No. 10, East Section of Fengcheng 3rd Road, Weiyang District, Xi'An, 710021, China.
Discov Oncol. 2025 May 13;16(1):751. doi: 10.1007/s12672-025-02345-1.
The pathogenesis of osteosarcoma remains inadequately understood. This study aims to investigate the role and underlying mechanisms of miR-301a-3p in osteosarcoma progression, providing a scientific basis for the development of effective therapeutic strategies.
Osteosarcoma tissues and cells were collected and miR-301a-3p expression was detected by qRT-PCR and assessed the correlation between miR-301a-3p expression and clinical disease and prognosis of osteosarcoma patients. The effects of miR-301a-3p overexpression on osteosarcoma cells were investigated by Transwell assay and CCK-8 assay. The targeting relationship between miR-301a-3p and MAFB was detected by dual luciferase reporter assay.
miR-301a-3p was significantly downregulated in osteosarcoma. Significant differences in TNM staging and lung metastasis were observed between the high and low miR-301a-3p expression groups, with a higher mortality rate in the low expression group, indicating it as a risk factor for poor prognosis. Upregulation of miR-301a-3p inhibited the proliferation and metastasis of osteosarcoma cells. MAFB was identified as a target gene of miR-301a-3p, capable of reversing the inhibitory effects of miR-301a-3p on cancer cells.
Low expression of miR-301a-3p may serve as a warning sign for disease progression and poor prognosis in osteosarcoma patients. miR-301a-3p may inhibit malignant behaviors of osteosarcoma cells by targeting MAFB. Future studies could explore the integration of ultrasound-targeted microbubble destruction technology to enhance the targeted delivery of miR-301a-3p mimics or MAFB inhibitors, potentially overcoming limitations in drug penetration and bioavailability observed in conventional therapies.
骨肉瘤的发病机制仍未得到充分了解。本研究旨在探讨miR-301a-3p在骨肉瘤进展中的作用及潜在机制，为制定有效的治疗策略提供科学依据。
收集骨肉瘤组织和细胞，采用qRT-PCR检测miR-301a-3p表达，并评估miR-301a-3p表达与骨肉瘤患者临床疾病及预后的相关性。通过Transwell实验和CCK-8实验研究miR-301a-3p过表达对骨肉瘤细胞的影响。采用双荧光素酶报告基因实验检测miR-301a-3p与MAFB之间的靶向关系。
miR-301a-3p在骨肉瘤中显著下调。miR-301a-3p高表达组和低表达组在TNM分期和肺转移方面存在显著差异，低表达组死亡率更高，表明其为预后不良的危险因素。miR-301a-3p的上调抑制了骨肉瘤细胞的增殖和转移。MAFB被鉴定为miR-301a-3p的靶基因，能够逆转miR-301a-3p对癌细胞的抑制作用。
miR-301a-3p低表达可能是骨肉瘤患者疾病进展和预后不良的警示信号。miR-301a-3p可能通过靶向MAFB抑制骨肉瘤细胞的恶性行为。未来的研究可以探索整合超声靶向微泡破坏技术，以增强miR-301a-3p模拟物或MAFB抑制剂的靶向递送，可能克服传统疗法中观察到的药物渗透和生物利用度方面的限制。
